Source-grounded facts extracted from CHARLES RIVER LABORATORIES INTERNATIONAL, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent auditors for fiscal 2026.
“(d) The shareholders approved the ratification of the appointment of PricewaterhouseCoopers LLP as our independent auditors for fiscal 2026.”
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. shareholders approved Approval of the 2026 Long-Term Incentive Plan.
“(c) The shareholders approved the 2026 Long-Term Incentive Plan.”
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. shareholders approved Advisory vote on named executive officer compensation.
“(b) The shareholders approved, on an advisory, non-binding basis, the compensation of our named executive officers.”
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. shareholders approved Election of twelve directors.
“(a) The following twelve (12) directors were elected to serve until our 2027 Annual Meeting of Shareholders and received the number of votes listed opposite each of their names below:”
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported first quarter ended March 28, 2026 results: revenue $995.8 million, net income $(14.8) million, EPS $(0.30). Guidance reaffirmed.
“Securities and Exchange Commission. --- EX-99.1 (EX-99.1) --- NEWS RELEASE CHARLES RIVER LABORATORIES ANNOUNCES FIRST-QUARTER 2026 RESULTS – Reports First-Quarter Revenue of $995.8 Million, GAAP Loss per Share of $(0.30), and Non-GAAP Earnings per Share of $2.06 – – Reaffirms 2026 Guidance for Organic Revenue and Non-GAAP Earnings per Share – – Repurchased $200”
Paul Graves was elected as Director at CHARLES RIVER LABORATORIES INTERNATIONAL, INC..
“the Board has agreed to, as promptly as practical following the Annual Meeting of Stockholders scheduled for May 20, 2025, to elect the Cooperation Agreement Directors as members of the Board (to fill the vacancies described in the preceding paragraph), effective immediately following such election”
Mark Enyedy was elected as Director at CHARLES RIVER LABORATORIES INTERNATIONAL, INC..
“the Board has agreed to, as promptly as practical following the Annual Meeting of Stockholders scheduled for May 20, 2025, to elect the Cooperation Agreement Directors as members of the Board (to fill the vacancies described in the preceding paragraph), effective immediately following such election”
Abe Ceesay was elected as Director at CHARLES RIVER LABORATORIES INTERNATIONAL, INC..
“the Board has agreed to, as promptly as practical following the Annual Meeting of Stockholders scheduled for May 20, 2025, to elect the Cooperation Agreement Directors as members of the Board (to fill the vacancies described in the preceding paragraph), effective immediately following such election”
Steven Barg was elected as Director at CHARLES RIVER LABORATORIES INTERNATIONAL, INC..
“the Board has agreed to, as promptly as practical following the Annual Meeting of Stockholders scheduled for May 20, 2025, to elect the Cooperation Agreement Directors as members of the Board (to fill the vacancies described in the preceding paragraph), effective immediately following such election”
Richard F. Wallman departed as Director at CHARLES RIVER LABORATORIES INTERNATIONAL, INC..
“On May 6, 2025, Robert Bertolini, Deborah T. Kochevar, George E. Massaro and Richard F. Wallman each notified the Company of his or her decision to not stand for re-election to the Board at the 2025 Annual Meeting following the expiration of their respective terms prior to the 2025 Annual Meeting (resulting in four vacancies on the Board).”
George E. Massaro departed as Director at CHARLES RIVER LABORATORIES INTERNATIONAL, INC..
“On May 6, 2025, Robert Bertolini, Deborah T. Kochevar, George E. Massaro and Richard F. Wallman each notified the Company of his or her decision to not stand for re-election to the Board at the 2025 Annual Meeting following the expiration of their respective terms prior to the 2025 Annual Meeting (resulting in four vacancies on the Board).”
Deborah T. Kochevar departed as Director at CHARLES RIVER LABORATORIES INTERNATIONAL, INC..
“On May 6, 2025, Robert Bertolini, Deborah T. Kochevar, George E. Massaro and Richard F. Wallman each notified the Company of his or her decision to not stand for re-election to the Board at the 2025 Annual Meeting following the expiration of their respective terms prior to the 2025 Annual Meeting (resulting in four vacancies on the Board).”
Robert Bertolini departed as Director at CHARLES RIVER LABORATORIES INTERNATIONAL, INC..
“On May 6, 2025, Robert Bertolini, Deborah T. Kochevar, George E. Massaro and Richard F. Wallman each notified the Company of his or her decision to not stand for re-election to the Board at the 2025 Annual Meeting following the expiration of their respective terms prior to the 2025 Annual Meeting (resulting in four vacancies on the Board).”
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. shareholders rejected Shareholder proposal to publish a report on non-human primates imported by the Company at the 2024-05-08 meeting.
“The shareholders did not approve the shareholder proposal submitted by PETA to publish a report on non-human primates imported by the Company.”
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. shareholders approved Ratification of PricewaterhouseCoopers LLP as independent auditors for fiscal 2024 at the 2024-05-08 meeting.
“The shareholders approved the ratification of the appointment of PricewaterhouseCoopers LLP as our independent auditors for fiscal 2024.”
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. shareholders approved Advisory, non-binding approval of named executive officer compensation at the 2024-05-08 meeting.
“The shareholders approved, on an advisory, non-binding basis, the compensation of our named executive officers.”
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. shareholders approved Election of eleven directors at the 2024-05-08 meeting.
“The following eleven (11) directors were elected to serve until our 2025 Annual Meeting of Shareholders and received the number of votes listed opposite each of their names below”
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported financial results for the first quarter ended March 30, 2024.
“On May 9, 2024, Charles River Laboratories International, Inc. issued a press release providing financial results for the first quarter ended March 30, 2024.”
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. updated its 2024 guidance (initiated).
“Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance”
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported the fiscal year ended December 30, 2023 results: revenue $4.13 billion, EPS $9.22 per share.
“Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance – Fourth-Quarter Revenue of $1.01 Billion and Full-Year Revenue of $4.13 Billion – – Fourth-Quarter GAAP Earnings per Share of $3.62 and Non-GAAP Earnings per Share of $2.46 – – Full-Year GAAP Earnings per Share of $9.22 and Non-GAAP Earnings per Share of $10.67 – – Provides 2024 Guidance –”
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported the fourth quarter ended December 30, 2023 results: revenue $1.01 billion, net income $187.1 million, EPS $3.62 per share.
“EXHIBIT 99.1 Exhibit 99.1 Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance – Fourth-Quarter Revenue of $1.01 Billion and Full-Year Revenue of $4.13 Billion – – Fourth-Quarter GAAP Earnings per Share of $3.62 and Non-GAAP Earnings per Share of $2.46 – – Full-Year GAAP Earnings per Share of $9.22”
Reshema Kemps-Polanco was appointed as Director at CHARLES RIVER LABORATORIES INTERNATIONAL, INC..
“Following the size increase of the Board, the Board filled the vacancy and appointed Ms. Reshema Kemps-Polanco to the Board.”
Kristen Eisenhauer changed role as Senior Vice President, Chief Commercial Officer at CHARLES RIVER LABORATORIES INTERNATIONAL, INC..
“Kristen Eisenhauer is assuming the role of Senior Vice President, Chief Commercial Officer.”
William D. Barbo departed as Corporate Executive Vice President and Chief Commercial Officer at CHARLES RIVER LABORATORIES INTERNATIONAL, INC..
“William D. Barbo, its Corporate Executive Vice President and Chief Commercial Officer, will retire from the Company at the end of 2024 after a distinguished, 42-year career with the Company.”
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported the third quarter of 2023 results: revenue $1.03 billion, net income $87.4 million, EPS $1.69. Guidance lowered.
“EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 a53773748ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Charles River Laboratories Announces Third-Quarter 2023 Results – Third-Quarter Revenue of $1.03 Billion – – Third-Quarter GAAP Earnings per Share of $1.69 and Non-GAAP Earnings per Share of $2.72 – – Updates 2023 Guidance – WILMINGTON, Mass.--(BUSINESS WIRE)--November 8,”
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported the second quarter of 2023 results: revenue $1.06 billion, EPS $1.89. Guidance reaffirmed.
“EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 a53513759ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Charles River Laboratories Announces Second-Quarter 2023 Results – Second-Quarter Revenue of $1.06 Billion – – Second-Quarter GAAP Earnings per Share of $1.89 and Non-GAAP Earnings per Share of $2.69 – – Updates 2023 Guidance – WILMINGTON, Mass.--(BUSINESS WIRE)--August 9,”
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. shareholders rejected Shareholder proposal to publish a report on non-human primates imported by the Company at the 2023-05-09 meeting.
“The shareholders did not approve the shareholder proposal submitted by PETA to publish a report on non-human primates imported by the Company. For Against Abstain Broker Non-Votes 16,382,651 29,395,105 233,421 1,946,418”
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent auditors at the 2023-05-09 meeting.
“The shareholders approved the ratification of the appointment of PricewaterhouseCoopers LLP as our independent auditors for fiscal 2023. For Against Abstain Broker Non-Votes 45,515,845 2,419,202 22,548 0”
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. shareholders approved Advisory vote on frequency of say-on-pay votes at the 2023-05-09 meeting.
“The shareholders voted for one year with respect to the frequency with which shareholders are provided a non-binding, advisory vote on compensation paid to our named executive officers. 1 Year 2 Years 3 Years Abstain Broker Non-Votes 45,471,178 10,778 515,767 13,454 1,946,418”
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. shareholders approved Advisory vote on executive compensation at the 2023-05-09 meeting.
“The shareholders approved, on an advisory, non-binding basis, the compensation of our named executive officers. For Against Abstain Broker Non-Votes 40,252,161 5,727,678 31,338 1,946,418”
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. shareholders approved Election of Directors at the 2023-05-09 meeting.
“The following eleven (11) directors were elected to serve until our 2024 Annual Meeting of Shareholders and received the number of votes listed opposite each of their names below: Number of Shares Voted For Number of Shares Voted Against Number of Shares Abstained Broker Non-Votes James C. Foster 43,579,312 2,358,658 73,207 1,946,418 Nancy C. Andrews 44,650,631 1,341,754 18,792 1,946,418 Robert J. Bertolini 44,516,198 1,475,422 19,557 1,946,418 Deborah T. Kochevar 39,420,122 6,572,677 18,378 1,946,418 George Llado, Sr. 43,662,653 2,329,118 19,406 1,946,418 Martin W. Mackay 28,520,093 17,471,571 19,513 1,946,418 George E. Massaro 43,360,879 2,632,513 17,785 1,946,418 C. Richard Reese 43,199,915 2,793,600 17,662 1,946,418 Craig B. Thompson 45,551,367 440,372 19,438 1,946,418 Richard F. Wallman 43,370,869 2,394,188 246,120 1,946,418 Virginia M. Wilson 44,631,226 1,363,328 16,623 1,946,418”
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported the first quarter ended April 1, 2023 results: revenue $1.03 billion, net income $103.1 million, EPS $2.01. Guidance reaffirmed.
“Charles River Laboratories Announces First-Quarter 2023 Results – First-Quarter Revenue of $1.03 Billion – – First-Quarter GAAP Earnings per Share of $2.01 and Non-GAAP Earnings per Share of $2.78 – – Updates 2023 Guidance –”
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported Full Year 2022 results: revenue $3.98 Billion, EPS $9.48.
“Charles River Laboratories Announces Fourth-Quarter and Full-Year 2022 Results and Provides 2023 Guidance – Fourth-Quarter Revenue of $1.10 Billion and Full-Year Revenue of $3.98 Billion – – Fourth-Quarter GAAP Earnings per Share of $3.65 and Non-GAAP Earnings per Share of $2.98 – – Full-Year GAAP Earnings per Share of $9.48 and Non-GAAP Earnings per Share of $11.12 – – Provides 2023 Guidance –”
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported Fourth Quarter 2022 results: revenue $1.10 Billion, net income $187.4 million, EPS $3.65.
“EXHIBIT 99.1 Exhibit 99.1 Charles River Laboratories Announces Fourth-Quarter and Full-Year 2022 Results and Provides 2023 Guidance – Fourth-Quarter Revenue of $1.10 Billion and Full-Year Revenue of $3.98 Billion – – Fourth-Quarter GAAP Earnings per Share of $3.65 and Non-GAAP Earnings per Share of $2.98 – – Full-Year GAAP Earnings per Share of $9.48”
Craig B. Thompson was appointed as Director at CHARLES RIVER LABORATORIES INTERNATIONAL, INC..
“Following the size increase of the Board, the Board filled the vacancy and appointed Dr. Craig B. Thompson to the Board.”
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported third quarter ended September 24, 2022 results: revenue $989.2 million, net income $96.5 million, EPS $1.88. Guidance reaffirmed.
“EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 a52958171ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Charles River Laboratories Announces Third-Quarter 2022 Results – Third-Quarter Revenue of $989.2 Million – – Third-Quarter GAAP Earnings per Share of $1.88 and Non-GAAP Earnings per Share of $2.63 – – Narrows 2022 Revenue Growth and Earnings Per Share Guidance – – Announces Planned”
Flavia H. Pease was appointed as Corporate Executive Vice President and Chief Financial Officer at CHARLES RIVER LABORATORIES INTERNATIONAL, INC..
“On March 28, 2022, the Company announced the appointment of Flavia H. Pease as its Corporate Vice President and Chief Financial Officer.”
David R. Smith retired as Corporate Executive Vice President and Chief Financial Officer at CHARLES RIVER LABORATORIES INTERNATIONAL, INC..
“Mr. Smith will step down from his position as Corporate Executive Vice President and Chief Financial Officer in connection with Flavia H. Pease’s appointment as the Company’s new Corporate Executive Vice President and Chief Financial Officer (as discussed below).”
David R. Smith departed as Corporate Executive Vice President and Chief Financial Officer at CHARLES RIVER LABORATORIES INTERNATIONAL, INC..
“On January 11, 2022, Charles River Laboratories International, Inc. (the “Company”) announced that David R. Smith, its Corporate Executive Vice President and Chief Financial Officer, will retire from the Company after a distinguished career in healthcare and finance leadership roles.”
Birgit Girshick was appointed as Chief Operating Officer at CHARLES RIVER LABORATORIES INTERNATIONAL, INC..
“On November 11, 2021, Charles River Laboratories International, Inc. (the "Company") announced that Ms. Birgit Girshick, Corporate Executive Vice President, Discovery and Safety Assessment and Biologics Testing Solutions, will become Chief Operating Officer of the Company, effective immediately, and will add Research Models and Services to her responsibilities.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.